Nilotinib
In the US, Nilotinib (nilotinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Chronic Myelogenous Leukemia.
US matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L01XE08
CAS registry number (Chemical Abstracts Service)
0641571-10-0
Chemical Formula
C28-H22-F3-N7-O
Molecular Weight
529
Therapeutic Categories
Cytostatic agent
Tyrosine kinase inhibitor
Chemical Names
4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide (WHO)
4-Methyl-N-[3-(4-methylmidazol-1-yl)-5-trifluormethylphenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamin)benzamid (IUPAC)
Foreign Names
- Nilotinibum (Latin)
- Nilotinib (German)
- Nilotinib (French)
- Nilotinib (Spanish)
Generic Names
- Nilotinib (OS: BAN)
- AMN-107 (IS: Novartis)
Brand Names
- Tasigna
Novartis, China; Novartis, Georgia; Novartis, Hong Kong; Novartis, Israel; Novartis, Malaysia; Novartis, Portugal; Novartis, Romania; Novartis, Singapore; Novartis, Slovenia; Novartis, Tunisia; Novartis, Turkey; Novartis, Taiwan; Novartis Farmaceutica, Spain; Novartis Healthcare, Philippines; Novartis, Australia; Novartis, Belgium; Novartis, Canada; Novartis, Switzerland; Novartis, Chile; Novartis, Czech Republic; Novartis, Germany; Novartis, Denmark; Novartis, Finland; Novartis, France; Novartis, United Kingdom; Novartis, Greece; Novartis, Croatia (Hrvatska); Novartis, Indonesia; Novartis, Ireland; Novartis, Iceland; Novartis, Japan; Novartis, South Korea; Novartis, Lithuania; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Oman; Novartis, Serbia; Novartis, Sweden; Novartis, Thailand; Novartis, United States; Novartis, South Africa; Novartis Europharm, Austria; Novartis Europharm Limited, Latvia; Novartis Farma, Italy
International Drug Name Search
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| IUPAC | International Union of Pure and Applied Chemistry |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| WHO | World Health Organization |
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
